Overview
Cetya Therapeutics, Inc. (“Cetya”) is a Delaware C-Corporation formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole. More than 30 largazole analogs have been synthesized, some with best-in-class profiles as HDACi including:
- Biochemical and cell-based potency
- Upregulation of fetal hemoglobin expression
- In-vivo anti-cancer activity
As a drug class, HDACis are effective in treating certain cancers, and thought leaders in epigenetics believe that this class of compounds may have broader application in treating other conditions such as:
- Hemoglobinopathies
- Immuno-oncology
- Chronic inflammation
- Neurological disorders
- Fibrotic diseases
Cetya has chosen to focus on hemoglobinopathies, specifically sickle cell disease (SCD) as its lead clinical indication.